BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//DEMENTIA RESEARCHER - ECPv6.14.0//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:DEMENTIA RESEARCHER
X-ORIGINAL-URL:https://www.dementiaresearcher.nihr.ac.uk
X-WR-CALDESC:Events for DEMENTIA RESEARCHER
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/London
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20260329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20261025T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261116
DTEND;VALUE=DATE:20261120
DTSTAMP:20260705T010253
CREATED:20260108T120508Z
LAST-MODIFIED:20260108T120508Z
UID:10002036-1794787200-1795132799@www.dementiaresearcher.nihr.ac.uk
SUMMARY:Clinical Trials on Alzheimer’s Disease Conference
DESCRIPTION:The Clinical Trials on Alzheimer’s Disease (CTAD) Conference\, established in 2008\, has become a cornerstone event in Alzheimer’s disease (AD) clinical research. Designed by and for AD researchers\, CTAD’s mission is to create a platform that prioritizes substantive\, clinical research-focused dialogue and collaboration. By fostering an intimate and collegial environment\, CTAD has gained a reputation for facilitating impactful international collaborations and advancing the global AD research agenda. \nThe upcoming 18th annual Clinical Trials on Alzheimer’s Disease Conference (CTAD26) to be held in Boston (USA) on November 16-19\, 2026. CTAD26 will build on the momentum of previous years\, reflecting the rapid advancements in Alzheimer’s disease diagnostics and therapeutics that make this field one of the most dynamic in medical research today. \nCTAD26 also features thought-provoking roundtables and symposia that explore the latest advancements in AD research. Renowned clinicians and leaders from academia\, research centers\, patient coalitions\, and pharmaceutical companies engage in dynamic discussions on diverse topics\, from disease-modifying agents to gene therapy\, vaccines\, and multimodal interventions. \nFind out More
URL:https://www.dementiaresearcher.nihr.ac.uk/event/clinical-trials-on-alzheimers-disease-conference/
LOCATION:Online\, United Kingdom
CATEGORIES:Conference
ATTACH;FMTTYPE=image/png:https://www.dementiaresearcher.nihr.ac.uk/wp-content/uploads/2025/07/CTAD-Logo-2025.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/London:20260710T100000
DTEND;TZID=Europe/London:20260710T170000
DTSTAMP:20260705T010253
CREATED:20260326T205154Z
LAST-MODIFIED:20260326T205230Z
UID:10002161-1783677600-1783702800@www.dementiaresearcher.nihr.ac.uk
SUMMARY:ITM2B Symposium
DESCRIPTION:How can an understudied gene teach us to fight dementia? The ITM2B Symposium is a research conference exploring clinical\, pathological and modelling advances in British dementia and other ITM2B related dementias. \nThis meeting brings together international experts to share the latest findings on disease mechanisms\, biomarkers\, and emerging approaches to understanding these rare but informative conditions. By focusing on ITM2B\, an often overlooked gene\, the symposium aims to uncover insights that may inform broader dementia research. \nDate and Location\n10 July 2026Kennedy Lecture Theatre\, ICH GOSH\, London\, UK \nThis is a hybrid event\, with options to attend in person or online. \nAttendance\n\nFree to attend\nOpen to all career stages and backgrounds\n\nSpeakers\n\nRuben Vidal\, Indiana University School of Medicine\, USA\nLuciano D’Adamio\, Rutgers Brain Health Institute\, USA\nSimon Mead\, UCL\, UK\nTamas Revesz\, UCL\, UK\nKo Woon Kim\, National University Hospital\, Jeonju\, South Korea\nJuliette Wohlschlegel\, University of Washington\, USA\n\nRegistration\nRegister by 10 June 2026 \nFor further information contact: c.arber@ucl.ac.uk \n\nRegister
URL:https://www.dementiaresearcher.nihr.ac.uk/event/itm2b-symposium/
LOCATION:UCL – Kennedy Lecture Theatre\, Institute of Child Health - Main Building\, 30 Guildford Street\, London\, Greater London\, WC1N 1EH\, United Kingdom
CATEGORIES:Conference,Online,Symposium
ATTACH;FMTTYPE=image/png:https://www.dementiaresearcher.nihr.ac.uk/wp-content/uploads/2026/03/ITM2B-Symposium.png
GEO:51.523309;-0.120066
X-APPLE-STRUCTURED-LOCATION;VALUE=URI;X-ADDRESS=UCL – Kennedy Lecture Theatre Institute of Child Health - Main Building 30 Guildford Street London Greater London WC1N 1EH United Kingdom;X-APPLE-RADIUS=500;X-TITLE=Institute of Child Health - Main Building\, 30 Guildford Street:geo:-0.120066,51.523309
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260707
DTEND;VALUE=DATE:20260711
DTSTAMP:20260705T010253
CREATED:20260519T164852Z
LAST-MODIFIED:20260519T164852Z
UID:10002251-1783382400-1783727999@www.dementiaresearcher.nihr.ac.uk
SUMMARY:Dementia UK Annual Summer School
DESCRIPTION:Tuesday 7th-Friday 10th July 2026 \nDementia UK is excited to host its free annual Summer School\, with the aim of improving practice in and knowledge of dementia care. \nWe invite all health and social care practitioners\, including students\, volunteer sector workers and allied professionals who have an interest in improving care and support for families living with dementia. \nOn this page\, you will find a description of the topics available during Summer School 2026 and links to registration forms. You are welcome to book as many or as few webinars as you like. \nIf you have any questions\, please contact ANacademy@dementiauk.org \n\nTuesday 7th July 2026\n10.30am-12pm Welcome to Dementia UK and Admiral Nursing \n\nWelcome to Dementia UK: the specialist dementia nursing charity\nAdmiral Nurses working across different settings\n\nRegister for this session \n2-4pm Practical tips and advice in dementia care \n\nTop tips from dementia carers: Lived Experience Advisory Panel (LEAP) discussion around risks in the home\nRisks in the home\n\nRegister for this session \nWednesday 8th July 2026\n10.30am-12pm Rarer types of dementia and tackling stigma  \n\nFrontotemporal dementia\nTackling the stigma in young onset dementia\n\nRegister for this session \n2-4pm Parkinson’s and Lewy body dementia \n\nParkinson’s and cognition: symptom management and treatment\nLewy body dementia: understanding the lived experience and supporting families – what works\n\nRegister for this session \nThursday 9th July 2026\n10.30am-12pm Honouring and supporting the LGTBQ+ community and dementia care \n\nLove\, legacy and memory: centring LGBTQ+ stories in dementia care\n\nRegister for this session \n2-4pm Honouring culturally responsive dementia care \n\nInclusive dementia care: cultural and religious considerations\nProtocols used in transcultural dementia care: supporting communities from diverse backgrounds\n\nRegister for this session \nFriday 10th July 2026\n10.30am-12.30pm Intimacy and sensory needs  \n\nPromoting intimacy in dementia care\nHearing loss and dementia: why hearing matters for brain health\nNavigating the complexity of real life: a family experience\n\nRegister for this session \nAll presentations are recorded and available on the Dementia UK YouTube channel.
URL:https://www.dementiaresearcher.nihr.ac.uk/event/dementia-uk-annual-summer-school/
LOCATION:Online\, United Kingdom
CATEGORIES:Training
ATTACH;FMTTYPE=image/jpeg:https://www.dementiaresearcher.nihr.ac.uk/wp-content/uploads/2022/06/Dementia-UK-e1655884462548.jpg
ORGANIZER;CN="Dementia UK":MAILTO:info@dementiauk.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/London:20260708T090000
DTEND;TZID=Europe/London:20260708T100000
DTSTAMP:20260705T010253
CREATED:20260618T201957Z
LAST-MODIFIED:20260618T201957Z
UID:10002291-1783501200-1783504800@www.dementiaresearcher.nihr.ac.uk
SUMMARY:UKDTN/ARUK - Clinical Trial Placement Pilot Programme
DESCRIPTION:The National Institute for Health and Care Research (NIHR) UK Dementia Trials Network (UKDTN) and Alzheimer’s Research UK (ARUK) are hosting a webinar to explore the Clinical Trial Placement Pilot Programme\, an optional component of the ARUK Doctoral Clinical Fellowship Programme. \nThis exciting opportunity is designed to give aspiring clinical academics hands-on experience in dementia clinical trials\, with the aim of developing future leaders in clinical trial research. The session will include short presentations introducing UKDTN’s mission and strategic goals by Professor John-Paul Taylor\, alongside an overview of the ARUK Doctoral Clinical Fellowship programme and placement opportunity\, presented by Eve Chapman. \nA panel discussion will follow featuring current UKDTN Clinical Trial Fellows sharing their perspectives on what it is like to be part of UKDTN and to work at the forefront of Alzheimer’s and dementia research. The webinar aims to inspire early career researchers to explore opportunities in clinical research and consider pursuing a similar path. \n\nRegister
URL:https://www.dementiaresearcher.nihr.ac.uk/event/ukdtn-aruk-clinical-trial-placement-pilot-programme/
LOCATION:Online\, United Kingdom
CATEGORIES:Online
ATTACH;FMTTYPE=image/png:https://www.dementiaresearcher.nihr.ac.uk/wp-content/uploads/2026/02/UKDTN-Logo.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/London:20260708T140000
DTEND;TZID=Europe/London:20260708T150000
DTSTAMP:20260705T010253
CREATED:20260618T205543Z
LAST-MODIFIED:20260618T205543Z
UID:10002292-1783519200-1783522800@www.dementiaresearcher.nihr.ac.uk
SUMMARY:Making Alzheimer’s Biomarkers More Accessible
DESCRIPTION:Join this 60-minute live webinar exploring practical advances in blood-based biomarker testing for Alzheimer’s disease (AD)\, with a focus on scalable and accessible quantitation of the optimal combination of biomarkers. \nDespite rapid growth in AD biomarker research\, it is not always clear which targets are the most meaningful and which measurement system best serves a given application. Quantitation methods range from highly specialized platforms requiring significant capital investment\, to simpler approaches with lower sensitivity. \nThis session will introduce a new cost-effective and sensitive (sub-pg/mL) biomarker detection platform and present findings on an AD 5-plex biomarker panel on well-characterized clinical samples. Preliminary data on an eMTBR-tau243 and BD pTau-217 duplex available for early-access will also be presented. \nThrough a structured webinar format combining expert presentation and moderated discussion\, participants will explore: \n\nConsiderations and tradeoffs for selecting biomarker quantitation methods\nDeep-dive into scalable ultrasensitive detection without capital equipment\nThe rational for targeted biomarker panels\, including why pTau-217\, Aβ42\, Aβ40\, NfL\, and GFAP were selected.\nEvaluate targeted biomarker panel performance in well-characterized clinical samples\n\nDesigned to support scientific exchange and practical understanding\, this session will provide a first look at evolving data and its potential implications for research and clinical workflows. \nFaculty \nChair: Marissa Lee\, PhD\, Director of Applications\, Taudia\nSpeaker: Noah Elder\, Director of R&D\, Taudia \nThis webinar is delivered in collaboration with Taudia. \n\nRegister
URL:https://www.dementiaresearcher.nihr.ac.uk/event/making-alzheimers-biomarkers-more-accessible/
LOCATION:Online\, United Kingdom
CATEGORIES:Lecture
ATTACH;FMTTYPE=image/png:https://www.dementiaresearcher.nihr.ac.uk/wp-content/uploads/2026/06/Making-Alzheimers-Biomarkers-More-Accessible.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/London:20260716T150000
DTEND;TZID=Europe/London:20260716T160000
DTSTAMP:20260705T010253
CREATED:20260625T201442Z
LAST-MODIFIED:20260625T201442Z
UID:10002300-1784214000-1784217600@www.dementiaresearcher.nihr.ac.uk
SUMMARY:Decoding complex disease through multiomics
DESCRIPTION:Complex diseases are shaped by polygenic risk\, regulatory variation\, and molecular mechanisms that cannot be fully explained by single-omics approaches. \nIn this webinar\, our expert speakers will discuss how multiomic Oxford Nanopore sequencing supports a deeper understanding of disease mechanisms\, by integrating DNA\, RNA\, and epigenetic analysis — all on a single platform. \nPLEASE NOTE: This webinar will be offered in two timezones. Please select your preferred option on the form below. \nYou will learn:\n\nHow multiomic Oxford Nanopore sequencing brings together characterisation of DNA variants\, RNA isoforms\, and DNA and RNA modifications for more comprehensive disease research.\nHow multiomic insights can support biomarker discovery and translational research into neurodegenerative conditions such as Alzheimer’s disease.\nHow Oxford Nanopore is unlocking new possibilities in RNA and cDNA sequencing\, with a new cDNA-PCR protocol generating longer\, more complete reads and more accurate isoform resolution than legacy technologies.\n\n\nMeet the speakers\nWalaa-Mohamed\, Market Segment Manager – Complex Disease\, Oxford Nanopore Technologies – Walaa is the Complex Disease Segment Market Manager at Oxford Nanopore Technologies. She works on supporting the adoption of long-read sequencing for the study of complex diseases. She has been at Oxford Nanopore Technologies for four years\, contributing to the advancement of genomics applications and translational research. Prior to joining Oxford Nanopore\, she worked as an R&D scientist at G42 on the validation phase of the Emirati Genome Project\, focusing on end-to-end workflow development and population-scale implementation. \nAshan Musafer\, Senior Field Application Scientist\, Oxford Nanopore Technologies – Ashan Musafer is a Senior Field Application Scientist at Oxford Nanopore Technologies with over a decade of expertise in translational genomics and epigenetics. He holds a Bachelor’s degree in Biomedical science from Monash University and a Master’s degree in Laboratory Medicine from the Royal Melbourne Institute of Technology (RMIT). Over the past 3 years at Oxford Nanopore\, Ashan has focused on technical enablement while supporting the planning\, implementation and execution of various genomic initiatives across the Gulf and Central Asian region. \nPatrick-Murphy\, Market Segment Manager – Single Cell\, Oxford Nanopore Technologies – At Oxford Nanopore Technologies\, Patrick Murphy works on single cell and bulk transcriptomics applications of Oxford Nanopore sequencing. He focuses on helping researchers understand where Oxford Nanopore sequencing approaches can add value to their transcriptomics studies\, including analysis of full-length RNA molecules\, isoforms\, splice variation\, and fusion transcripts. \n\nClick Here
URL:https://www.dementiaresearcher.nihr.ac.uk/event/decoding-complex-disease-through-multiomics/
LOCATION:Online\, United Kingdom
CATEGORIES:Workshop
ATTACH;FMTTYPE=image/png:https://www.dementiaresearcher.nihr.ac.uk/wp-content/uploads/2023/01/Nanopore-Technology.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/London:20260716T143000
DTEND;TZID=Europe/London:20260716T153000
DTSTAMP:20260705T010253
CREATED:20260702T090739Z
LAST-MODIFIED:20260702T090739Z
UID:10002307-1784212200-1784215800@www.dementiaresearcher.nihr.ac.uk
SUMMARY:Launch of WHO’s guidelines for risk reduction of cognitive decline and dementia
DESCRIPTION:WHO Global Webinar: Launch of the Second Edition of the WHO Guidelines on Risk Reduction of Cognitive Decline and Dementia\nThe World Health Organization is hosting a global webinar to launch the second edition of its guidelines on the risk reduction of cognitive decline and dementia. \nThis high-level online event will bring together people with lived experience\, scientific experts and country representatives to mark the publication of the updated guidelines. \nThe new edition reflects the latest available evidence and provides practical recommendations to help countries\, health systems and communities strengthen dementia risk reduction across the life course. The webinar will introduce the new and updated recommendations\, explore what they mean in practice\, and consider actions that can support better brain health at individual\, community and system level. \nThis event will be particularly relevant for researchers\, clinicians\, policy makers\, public health professionals\, dementia organisations\, and anyone with an interest in prevention\, brain health and dementia risk reduction. \nThe webinar will be held in English\, with interpretation available in French\, Portuguese and Spanish. \nDate: Thursday\, 16 July 2026\nTime: 3:30 p.m. CEST / 2:30 p.m. BST\nLocation: Online via Zoom\nTopic: Launch of the second edition of the WHO guidelines on risk reduction of cognitive decline and dementia\nHosted by: World Health Organization \nRegister in advance for the webinar using the link below. After registering\, you will receive a confirmation email with details on how to join. \n\nRegister Here
URL:https://www.dementiaresearcher.nihr.ac.uk/event/launch-of-whos-guidelines-for-risk-reduction-of-cognitive-decline-and-dementia/
LOCATION:Online\, United Kingdom
CATEGORIES:Public Discussion
ATTACH;FMTTYPE=image/png:https://www.dementiaresearcher.nihr.ac.uk/wp-content/uploads/2026/07/Untitled-02-July-2026-at-100634.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/London:20260728T130000
DTEND;TZID=Europe/London:20260728T140000
DTSTAMP:20260705T010253
CREATED:20260702T101510Z
LAST-MODIFIED:20260702T101510Z
UID:10002308-1785243600-1785247200@www.dementiaresearcher.nihr.ac.uk
SUMMARY:WHO Guidelines: Reducing Dementia Risk
DESCRIPTION:Co-hosted with the World Health Organization (WHO) join Alzheimer’s Disease International (ADI) for a special webinar to mark the release of the WHO’s updated dementia risk reduction guidelines. \nIn May 2017\, WHO Member States endorsed the Global action plan on the public health response to dementia\, committing to comprehensive\, multisectoral action on dementia\, including a dedicated focus on dementia risk reduction. \nIn the absence of a cure\, and access to disease modifying treatment being limited globally\, reducing dementia risk is a critical public health priority and an accessible strategy for many health authorities around the world. This is particularly pertinent given recent research suggesting that as many as 45% of dementias could be delayed or prevented. \nIn 2019\, WHO issued evidence-based guidelines on risk reduction in line with evidence that modifiable risk factors through life course interventions can delay or reduce cognitive decline and dementia. Since their publication\, the scientific evidence base has expanded\, including multidomain interventions\, population-level policies and additional risk factors. In light of strengthening evidence\, WHO developed updated dementia risk reduction guidelines. \nThis webinar will focus on the role that national associations and other stakeholders can play in the implementation of the guidelines and thereby aims to strengthen dementia risk reduction efforts globally\, accelerate implementation of the global action plan—particularly in low and middle-income countries – and promote integration with broader public health\, NCD and healthy ageing agendas. \nHosted by Acting CEO Chris Lynch\, the webinar will welcome ADI member associations and WHO representatives to reflect on the updated guidelines\, followed by a Q&A discussion. \nWe are pleased to offer AI translation for this webinar in 60+ languages. The webinar will be available for viewing on ADI’s YouTube channel after the event. \n\nRegister
URL:https://www.dementiaresearcher.nihr.ac.uk/event/who-guidelines-reducing-dementia-risk/
LOCATION:Online\, United Kingdom
CATEGORIES:Workshop
ATTACH;FMTTYPE=image/png:https://www.dementiaresearcher.nihr.ac.uk/wp-content/uploads/2020/05/ADI-e1606238565168.png
END:VEVENT
END:VCALENDAR